BAD HOMBURG, Germany—Fresenius saw its 2010 third quarter net revenue rise 6 percent over last year to $3.06 billion as its dialysis services revenue increased 8 percent to $2.32 billion.
However, Fresenius’ dialysis product third quarter revenue decreased by 1 percent to $737 million between 2009 and 2010.Fresenius’ North American revenue increased 6 percent to $2.07 billion, and dialysis services there grew 7 percent to $1.86 billion in the third quarter.
The average revenue per treatment for U.S. clinics increased to $359 in the third quarter of 2010 compared to $348 for the same quarter in 2009 and $356 for the second quarter of 2010. Fresenius said the increase was attributable principally to reimbursement increases.
Dialysis product revenue in North America slightly decreased from $209 million in the third quarter of 2009 to $208 million in the third quarter of 2010. Sales performance was impacted favorably by higher sales of bloodlines and machines as well as higher product sales in the home therapy market, according to Fresenius. This was offset by changes in the dialysis products mix and lower Medicare average selling prices (ASP) for the intravenous iron product Venofer.
In North America, the operating margin increased from 16.7 percent to 18.1 percent. The margin development benefitted primarily from an increase in revenue per treatment as well as the effect of economies of scale.
As of Sept. 30, Fresenius reported that it treated 210,191 patients worldwide, which represents a 9 percent increase compared to the previous year. North America provided dialysis treatments for 135,746 patients, the number of patients treated rose by 4 percent.Including 30 clinics managed by Fresenius Medical Care North America the number of patients in North America was 137,623. The International segment served 74,445 patients, the number of patients treated increased by 20 percent.
In addition, Fresenius has a total of 2,716 clinics worldwide, which represents an 8 percent increase compared to the previous year. The number of clinics is comprised of 1,809 clinics in North America (1,839 including managed clinics) and 907 clinics in the International segment, representing an increase of 3 percent and 19 percent, respectively.
Fresenius said delivered approximately 23.41 million dialysis treatments worldwide during the first nine months of 2010. This represents an increase of 7 percent compared to the corresponding period last year. North America accounted for 15.51 million treatments, an increase of 5 percent and the International segment delivered 7.9 million treatments, an increase of 11 percent.
